Adherence to endocrine therapy in breast cancer adjuvant and prevention settings

Cancer Prevention Research

Volumn 7, Issue 4, 2014, Pages 378-387

  Chlebowski, Rowan T ^a   Kim, Jisang ^a   Haque, Reina ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); HUMAN; MEDICATION COMPLIANCE; ONCOLOGIST; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; FEMALE;

AROMATASE INHIBITOR;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; PATIENT COMPLIANCE;

EID: 84898922722     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0389     Document Type: Review

References (84)

1. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61. (Pubitemid 34552485)
2. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6. (Pubitemid 46621892)
3. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9.
4. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at five years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013;381:805-16.
5. Gray RD, Rea DW, Handley K, Marshall A, Pritchard MG, Perry P, et al. aTTom (adjuvant tamoxifen - to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - preliminary results. J Clin Oncol 2008;26:513.
6. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42-45.
7. Oberguggenberger AS, Sztankay M, Beer B, Schubert B, Meraner V, Oberacher H, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer 2012;12:474.
8. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Annals of Oncol 2009;20:431-6.
9. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill count, and microelectronic monitoring. J Clin Oncol 1993;11:1189-97. (Pubitemid 23163362)
10. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62. (Pubitemid 351264348)
11. Fisher B, Constantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
12. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
13. van Herk-Sukel MP, van de Poll-Franse LV, Voogd CA, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 2010;122:843-51.
14. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 2011;130:681-9.
15. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-83. (Pubitemid 47477264)
16. Chlebowski RT, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, et al. Clinical perspectives on utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009;18 Suppl. 2:S1-11.
17. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Clin Oncol 2009;27:3235-58.
18. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of five years adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
19. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. (Pubitemid 38298988)
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy early-stage breast cancer. N Engl J Med 2003;349:1793-802. (Pubitemid 37362955)
21. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459-78.
22. Huiart L, Ferdynus C, Giorgi R. A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: a summarizing the data for clinicians. Breast Cancer Res Treat 2013;138:325-8.
23. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-8.
24. Ayres LR, Baldoni AD, Borges AP, Pereira LR. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm 2013;36:45-54.
25. Huiart L, Dell'Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 2011;104:1558-68.
26. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013;138:185-91.
27. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment emergent symptoms in early stage breast cancer. J Clin Oncol 2012;30:936-42.
28. Early Breast Cancer Trialist Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001; CD 000486.
29. Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 2008;206:66-75. (Pubitemid 350267255)
30. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-8.
31. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529-37.
32. Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, et al. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med 2012;1:318-27.
33. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013;108:1515-24.
34. Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernström H. Clinical profiles predict early non-adherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res 2012;5:735-745.
35. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol 2013;36:181-7.
36. Pagani O, Gelber S, Colleoni M, Price KN, Simoncini E. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-39 and 14-39. Breast Cancer Res Treat 2013;142:455-9.
37. Xu S, Yang Y, Tao W, Song Y, Chen Y, Ren Y, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Research Treat 2012;13:495-502.
38. Livaudais JC, Hershman DL, Habel L, Kushi L, Gomez SL, Li CI, et al. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 2012;131:607-617.
39. Livaudais J, LaCroix A, Chlebowski RT, Li CI, Habel LA, Simon MS, et al. Use of and adherence to adjuvant hormonal therapy for breast cancer in the Women's Health Initiative. Cancer Epidemiol Biomark Prev 2013;22:365-73.
40. Friese CR, Pini TM, Li Y, Abrahamse PH, Graff JJ, Hamilton AS, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 2013;138:931-9.
41. Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of the linguistic study focusing on adherence and persistence to therapy. J Support Oncol 2007;5:139-43. (Pubitemid 46779582)
42. Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 2012;107:1249-56.
43. Fontaine DB, Nortier JW, Liefers GJ, Putter H, Meershoek-Klein KE, van den Bosch J, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol 2012;3:107-7.
44. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomized prevention trial. Lancet 2002;360:817-24. (Pubitemid 35257944)
45. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-90. (Pubitemid 47073491)
46. Land SR, Wickerham DL, Constantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or tamoxifen for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
47. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;365:2381-91.
48. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
49. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncolo 2012;13:476-86.
50. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WMP, et al. Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial. Cancer Prev Res 2011;4:1393-1400.
51. Maurice A, Howell A, Evans DG, O'Neil AC, Scobie S. Predicting compliance in a breast cancer prevention trial. Breast J 2006;12:446-50. (Pubitemid 44337438)
52. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134:875-80.
53. Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627-33.
54. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuing in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22:3309-15. (Pubitemid 41103687)
55. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation older women. J Clin Oncol 2001;19:322-8. (Pubitemid 32112842)
56. Kahn KL, Shneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Medical Care 2007;45:41-9.
57. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215-20. (Pubitemid 44268270)
58. Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55. (Pubitemid 351264347)
59. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;7:156-66.
60. Riley GF, Warren JL, Harlan LC, Blackwell SA. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare part D. Medicare Medicaid Res Rev 2011;1.
61. Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29:2534-42.
62. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125:191-200.
63. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009;27:3445-51.
64. Pellegrini I, Sarradon-Eck A, Sooussan PB, Lacour AC, Largillier R, Tallet A, et al. Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patient's point of view. Psychooncology 2010;19:472-9.
65. Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012;23:882-890.
66. Liu Y, Malin JL, Diamart AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 2013;137:829-36.
67. Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, et al. Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus 2013;2:356.
68. Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 2012;8:e149-57.
69. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005;330:702.
70. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66.
71. Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P, et al. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer: results of the COMPAS study. Climacteric 2013 Aug 25. [Epub ahead of print].
72. Land SR, Wieand S, Day R, Ten Have T, Costantino JP, Lang W, et al. Methodological issues in the analysis of quality of life data in clinical trials: illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. Statistical Methods for Quality of Life Studies 2002:71-85.
73. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 2001;93:1615-23. (Pubitemid 33094868)
74. Moore S. Adherence to oral therapies for cancer: barriers and models for change? J Adv Pract Oncol 2010;1:155-164.
75. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res 2011;4:1360-5.
76. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, et al. The Patient's Anastrozole Compliance to Therapy (PACT) program: a randomized, in practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early stage breast cancer. Ann Oncol 2013;24:1505-12.
77. Ziller V, Kyvernitakis I, Knoll D, Storch A, Hars O, Hadji P, et al. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. BMC Cancer 2013;13:407.
78. Sohl SJ, Schnur JB, Montgomery GH. A meta-analysis of the relationship between response expectancies and cancer treatment-related side effects. J Pain Symptom Manage 2009;38:775-84.
79. Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen EC, et al. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol 2013;24:2324-9.
80. Von Blackenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 2013;13:426.
81. Cicolini G, Simonetti V, Comparcini D, Celiberti I, Di Nicola M, Capasso LM, et al. Efficacy of a nurse-led email reminder program for cardiovascular prevention risk reduction in hypertensive patients: a randomized controlled trial. Int J Nurs Stud 2013 Oct 25. [Epub ahead of print].
82. Becker S, Kribben A, Meister S, Diamantidis CJ, Unger N, Mitchell A, et al. User profiles of a smartphone application to support drug adherence - experience from the iNephro project. PLoS One 2013;8:e78547.
83. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication. Ann Pharmacother 2013;47:1448-56.
84. Carter MC, Burley VJ, Nykjaer C, Cade JE. Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial. J Med Internet Res 2013;15:e32.